Kercheville Advisors LLC raised its position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 62.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,725 shares of the exchange traded fund’s stock after acquiring an additional 6,045 shares during the quarter. Kercheville Advisors LLC’s holdings in SPDR S&P Biotech ETF were worth $1,554,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. ORG Partners LLC purchased a new stake in shares of SPDR S&P Biotech ETF in the 2nd quarter valued at approximately $40,000. ORG Wealth Partners LLC purchased a new position in SPDR S&P Biotech ETF in the third quarter valued at $44,000. Waldron Private Wealth LLC acquired a new stake in SPDR S&P Biotech ETF in the third quarter valued at $54,000. Resources Management Corp CT ADV boosted its position in shares of SPDR S&P Biotech ETF by 30.3% during the 2nd quarter. Resources Management Corp CT ADV now owns 593 shares of the exchange traded fund’s stock worth $55,000 after acquiring an additional 138 shares in the last quarter. Finally, Lynx Investment Advisory purchased a new position in shares of SPDR S&P Biotech ETF in the 2nd quarter valued at about $58,000.
SPDR S&P Biotech ETF Stock Performance
Shares of NYSEARCA XBI opened at $97.15 on Monday. The firm has a market capitalization of $7.40 billion, a PE ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a fifty-two week low of $63.80 and a fifty-two week high of $103.52. The stock’s 50-day simple moving average is $99.14 and its 200-day simple moving average is $94.65.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- High Flyers: 3 Natural Gas Stocks for March 2022
- GM’s Lithium Americas Deal Positions It for EV Dominance
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Amazon: Why Analysts Think It’s A Solid Buy Ahead Of Earnings
- What is a buyback in stocks? A comprehensive guide for investors
- NextEra’s Diverse Business Is Set to Win As Energy Demand Rises
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.